adalimumab-aacf (Idacio) vs adalimumab-bwwd (Hadlima)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TNF-alpha · full Psoriasis pipeline
adalimumab-aacf (Idacio)
Marketed by Fresenius SE & Co. KGaA
NCT02660580 · Phase 3 · completed
This was a randomized, double-blind, active-controlled phase 3 trial with 443 participants, using the clinical psoriasis endpoint PASI 75 at Week 16. MSB11022 met the prespecified equivalence criterion versus EU-Humira: the 95% confidence interval for the treatment difference was -7.82% to 4.07%, within the predefined -18% to 18% range.
No aligned efficacy figure on record for this race.
adalimumab-bwwd (Hadlima)
Marketed by Samsung Bioepis and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-aacf (Idacio) | adalimumab-bwwd (Hadlima) |
|---|---|---|
| PASI 75 | —Not reported | —Not reported |
| PASI 90 | —Not reported | —Not reported |
| PASI 100 | —Not reported | —Not reported |
| sPGA 0/1 | —Not reported | —Not reported |
| DLQI, change | —Not reported | —Not reported |
PASI 75
- adalimumab-aacf (Idacio)
- —Not reported
- adalimumab-bwwd (Hadlima)
- —Not reported
PASI 90
- adalimumab-aacf (Idacio)
- —Not reported
- adalimumab-bwwd (Hadlima)
- —Not reported
PASI 100
- adalimumab-aacf (Idacio)
- —Not reported
- adalimumab-bwwd (Hadlima)
- —Not reported
sPGA 0/1
- adalimumab-aacf (Idacio)
- —Not reported
- adalimumab-bwwd (Hadlima)
- —Not reported
DLQI, change
- adalimumab-aacf (Idacio)
- —Not reported
- adalimumab-bwwd (Hadlima)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-aacf (Idacio): registry results are on file for Psoriasis, but their comparison mappings are not yet available.
adalimumab-bwwd (Hadlima): no structured comparison results are available for Psoriasis.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-aacf (Idacio)'s landscape · adalimumab-bwwd (Hadlima)'s landscape